Platelet count predicts prognosis in operable non‑small cell lung cancer

Dangfan,Yu; Bingjiang,Liu; Lizhen,Zhang; Kaiqi,Du

doi:10.3892/etm.2013.1003

Platelet count predicts prognosis in operable non‑small cell lung cancer

Authors:
- Yu Dangfan
- Liu Bingjiang
- Zhang Lizhen
- Du Kaiqi
View Affiliations

Affiliations: Department of Radiology, Zhejiang Provincial Corps Hospital, Chinese People's Armed Police Force, Jiaxing, Zhejiang 314000, P.R. China, Department of Thoracic Surgery, Zhejiang Provincial Corps Hospital, Chinese People's Armed Police Force, Jiaxing, Zhejiang 314000, P.R. China
Published online on: March 12, 2013 https://doi.org/10.3892/etm.2013.1003
Pages: 1351-1354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platelets play a significant role in cancer cell growth, progression and metastasis. However, in non‑small cell lung cancer (NSCLC), the association between a patient's platelet count and prognosis has not previously been fully elucidated. The aim of the present study was to investigate the correlation between platelet count, patients' characteristics and prognosis in patients with NSCLC. A total of 510 NSCLC patients were enrolled in the present study. The median platelet count in the NSCLC patients was 203x109/l (95% CI, 115‑358x109/l). The median platelet count in T3 and T4 patients was significantly higher than that of T1 and T2 patients (median, 263x109/l and 253.5x109/l vs. 199.5x109/l and 196.5x109/l, respectively; P<0.001). The 3‑year cumulative overall survival (OS) probability was 75.3% for patients with normal platelet counts and 59.2% for patients with elevated platelet counts. When compared with the patients with normal platelet counts, the patients with elevated platelet counts had an increased risk of disease progression (HR, 1.568; 95% CI, 1.015‑2.453). Pre‑operative platelet counts are a novel independent prognostic biomarker in operable NSCLC.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2.	O’Byrne KJ, Gatzemeier U, Bondarenko I, et al: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 12:795–805. 2011.PubMed/NCBI
3.	Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 28:744–752. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Komurcuoglu B, Ulusoy S, Gayaf M, et al: Prognostic value of plasma D-dimer levels in lung carcinoma. Tumori. 97:743–748. 2011.PubMed/NCBI
5.	Unsal E, Atalay F, Atikcan S and Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 98:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
6.	van Doormaal FF, Raskob GE, Davidson BL, et al: Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 101:762–769. 2009.PubMed/NCBI
7.	Monreal M, Fernandez-Llamazares J, Piñol M, et al: Platelet count and survival in patients with colorectal cancer - a preliminary study. Thromb Haemost. 79:916–918. 1998.PubMed/NCBI
8.	Costantini V, Zacharski LR, Moritz TE and Edwards RL: The platelet count in carcinoma of the lung and colon. Thromb Haemost. 64:501–505. 1990.PubMed/NCBI
9.	Shimada H, Oohira G, Okazumi S, et al: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 198:737–741. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Ikeda M, Furukawa H, Imamura H, et al: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 9:287–291. 2002. View Article : Google Scholar : PubMed/NCBI
11.	Hwang SG, Kim KM, Cheong JH, et al: Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 38:562–567. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, et al: Platelet count: association with prognosis in lung cancer. Med Oncol. 27:357–362. 2010.PubMed/NCBI
13.	Gislason T and Nõu E: Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: an epidemiological study. Eur J Respir Dis. 66:141–146. 1985.PubMed/NCBI
14.	Engan T and Hannisdal E: Blood analyses as prognostic factors in primary lung cancer. Acta Oncol. 29:151–154. 1990. View Article : Google Scholar : PubMed/NCBI
15.	Pedersen LM and Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 9:1826–1830. 1996. View Article : Google Scholar : PubMed/NCBI
16.	Aoe K, Hiraki A, Ueoka H, et al: Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration. 71:170–173. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Cox G, Walker RA, Andi A, et al: Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer. 29:169–177. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Tomita M, Shimizu T, Hara M, et al: Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 7:613–615. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Dineen SP, Roland CL, Toombs JE, et al: The acellular fraction of stored platelets promotes tumor cell invasion. J Surg Res. 153:132–137. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Pipili-Synetos E, Papadimitriou E and Maragoudakis ME: Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol. 125:1252–1257. 1998. View Article : Google Scholar : PubMed/NCBI
21.	Placke T, Kopp HG and Salih HR: Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 3:374–382. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Nieswandt B, Hafner M, Echtenacher B and Männel DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59:1295–1300. 1999.PubMed/NCBI